Akari Therapeutics (AKTX) Assets Average (2012 - 2026)
Akari Therapeutics recorded quarterly Assets Average of $40.9 million in Q1 2026, down 12.32% quarter-over-quarter from $46.6 million in Q4 2025, and down 19.44% year-over-year from $50.8 million in Q1 2025.
Akari Therapeutics' Assets Average history runs 13 years deep, the most recent figure standing at $40.9 million for Q1 2026.
- In Q1 2026, Assets Average fell 19.44% year-over-year to $40.9 million; the TTM figure through Mar 2026 stood at $40.9 million (down 19.44% YoY), while the FY2025 annual figure was $49.2 million, up 79.28% from the prior year.
- Assets Average came in at $40.9 million for Q1 2026 at Akari Therapeutics, down from $46.6 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $19.3 billion in Q1 2022 to a low of $3.6 million in Q1 2024.
- A 4-year average of $1.6 billion and a median of $33.8 million in 2024 frame the typical range for Assets Average.
- Across the five-year window, Assets Average sank 99.93% in 2022 and jumped 1324.46% in 2025, its largest moves.
- Akari Therapeutics' Assets Average stood at $12.6 million in 2022, then soared by 111.47% to $26.6 million in 2024, then soared by 75.0% to $46.6 million in 2025, then declined by 12.32% to $40.9 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $40.9 million, $46.6 million, and $48.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 13.04 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 33.42 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.72 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 331.70 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 40.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.06 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 26.03 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.71 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.05 Bn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | 2.30 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 40.89 Mn |
| Dec 31, 2025 | 46.63 Mn |
| Sep 30, 2025 | 48.14 Mn |
| Jun 30, 2025 | 50.94 Mn |
| Mar 31, 2025 | 50.76 Mn |
| Dec 31, 2024 | 26.65 Mn |
| Sep 30, 2024 | 3.91 Mn |
| Jun 30, 2024 | 3.92 Mn |
| Mar 31, 2024 | 3.56 Mn |
| Dec 31, 2022 | 12.60 Mn |
| Jun 30, 2022 | 15.41 Mn |
| Mar 31, 2022 | 19.25 Bn |
| Dec 31, 2021 | 19.25 Bn |
| Sep 30, 2021 | 9.77 Mn |
| Jun 30, 2021 | 6.33 Mn |
| Mar 31, 2021 | 3.94 Mn |
| Dec 31, 2020 | 6.87 Mn |
| Sep 30, 2020 | 14.07 Mn |
| Jun 30, 2020 | 12.07 Mn |
| Mar 31, 2020 | 4.86 Mn |
| Dec 31, 2019 | 5.15 Mn |
| Sep 30, 2019 | 7.44 Mn |
| Jun 30, 2019 | 6.42 Mn |
| Mar 31, 2019 | 20.37 Bn |
| Dec 31, 2018 | 20.37 Bn |
| Sep 30, 2018 | 14.87 Mn |
| Jun 30, 2018 | 21.31 Mn |
| Mar 31, 2018 | 30.97 Bn |
| Dec 31, 2017 | 30.97 Bn |
| Sep 30, 2017 | 27.24 Mn |
| Jun 30, 2017 | 34.29 Mn |
| Mar 31, 2017 | 35.08 Bn |
| Dec 31, 2016 | 35.09 Bn |
| Sep 30, 2016 | 54.85 Mn |
| Jun 30, 2016 | 60.30 Mn |
| Mar 31, 2016 | 46.73 Bn |
| Dec 31, 2015 | 46.74 Bn |
| Sep 30, 2015 | 41.07 Mn |
| Jun 30, 2015 | 3.64 Mn |
| Mar 31, 2015 | 3.86 Mn |
| Dec 31, 2013 | 4.48 Mn |
| Dec 31, 2012 | 573,500.00 |